Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BL-B01D1 versus physician's choice chemotherapy in previously treated recurrent or metastatic nasopharyngeal carcinoma
CTR20233419Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in nasopharyngeal carcinoma (NPC), sponsored by Biokin Pharmaceutical. Started Dec 2023; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20233419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233419.